Homenewsabout usContact UsWebsite
Welcome to the
Cipla Press Office
Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support.
Follow us:

Latest news

Cipla launches affordable tetanus vaccine to prevent tetanus deathsWhile the world remains focused on containing the spread of Covid-19, this should not avert our attention away from the ongoing battle to eradicate the many other diseases that can affect the quality of life for millions of South Africans. 8 Dec 2020 Read more

Landmark oncology drug registrationIn what is groundbreaking news for cancer sufferers diagnosed with blood cancers such as multiple myeloma (MM) or myelodysplastic syndromes, Cipla recently received regulatory approval for lenalidomide - a lifesaving immunomodulatory drug that activates and increases the number of immune system cells that identify and attack cancer cells - to bring this medication into the South African market at affordable prices. This will help to ensure that more cancer patients have access to this treatment, in line with Cipla's ethos of 'caring for life'. 7 Dec 2020 Read more

Alvotech and Cipla partner to ensure access to biosimilars in South AfricaBiopharmaceutical company Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa. The biosimilar portfolio will include five biosimilar medicines - two for oncology and three for treating auto-immune diseases. 5 Nov 2020 Read more

IDA awards top industry honour to Greater Tygerberg PartnershipIDA presents awards recognising innovative achievement in urban place management 12 Oct 2020 Read more

Covid-19 drug, Remdesivir, arrives in SARemdesivir, a medicine which could make a difference in the management of severe Covid-19 disease, is available in South Africa now. Cipla obtained authorisation from the South African Health Products Regulatory Authority ("SAHPRA") to import this medicine under Section 21 of the Medicines and Related Substances Act. Cipla is working closely with SAHPRA and healthcare facilities to ensure access to remdesivir. 4 Aug 2020 Read more

More news...

Contact Cipla

Email: az.oc.alpic@ofni
Tel: +27 21 943 4200
Customer Care: 080 222 6662